Biotechnology equities can offer extraordinary capital appreciation potential driven by groundbreaking clinical breakthroughs, drug approvals, and corporate acquisition buyouts. However, they simultaneously carry high binary risks, severe price volatility, and heavy dependence on ongoing clinical trial results and regulatory decisions. Financial planners generally suggest limiting biotech exposure to a carefully diversified portion of a growth-oriented portfolio. What is your personal risk profile and target investment horizon?